Drugs / Oshadi Icp
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01772251 | Feb → Jun 2013 | type 1 diabetes mellitus | Oshadi Drug Administration | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01973920 | Dec 2013 → Feb 2017 | type 1 diabetes mellitus | Oshadi Drug Administration | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oshadi Icp | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01973920 ↗ |
| Modality | Protein / enzyme biologic | “Oshadi Icp - insulin, proinsulin and C-peptide in Oshadi carrier” NCT01772251 ↗ |
| Route | Oral | “Oshadi has also developed the Oshadi Icp - insulin, proinsulin and C-peptide in Oshadi carrier, administrated orally.” NCT01772251 ↗ |